Brief: Celltrion Inc Receives Final Market Approval For Steqeyma, Used For The Treatment Of Paediatric Plaque Psoriasis, Psoriatic Arthritis, And Crohn’S Disease From The European Commission
26/08/2024 02:42
Celltrion Inc 068270.KS :
* CELLTRION INC: RECEIVES FINAL MARKET APPROVAL FOR
STEQEYMA, USED
FOR THE TREATMENT OF PAEDIATRIC PLAQUE PSORIASIS, PSORIATIC
ARTHRITIS, AND CROHN’S DISEASE FROM THE EUROPEAN COMMISSION
Source text for Eikon: ID:
Further company coverage: 068270.KS
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares